Novo Nordisk's Ozempic shortage expected to continue into Q4
Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased demand and along with capacity constraints at some of its manufacturing sites.
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
Novo Nordisk 's ( NVO 1.19%) GLP-1 medicines, Ozempic and Wegovy, are bestsellers and household names. Whereas Ozempic is indicated for type 2 diabetes, Wegovy is prescribed for weight loss in the context of obesity. But, if some new information holds true, the company could soon see its presence in both of those markets take a hit.
Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices
CEO Lars Fruergaard Jørgensen has defended the high U.S. prices of the company’s blockbuster drugs, Ozempic and Wegovy, stating that these medications are reducing the economic burden of obesity-related health issues.
Medicare coverage of Novo Nordisk's Wegovy could cost up to $145B annually
Novo Nordisk's (NVO) weight loss drug Wegovy (semaglutide), which can be prescribed to Medicare beneficiaries who are both obese and have cardiovascular disease, could cost the system up to $145B per year. If all beneficiaries who are eligible for Wegovy ...
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
However, various potential headwinds have popped up that could disrupt Ozempic's progress. One of them is competition. Novo Nordisk's longtime foe in the diabetes market, Eli Lilly, developed Mounjaro, a diabetes medicine whose sales are growing incredibly fast.
Novo Nordisk CEO defends high price off Ozempic and Wegovy
NBC News' Meagan Fitzgerald sits down with Novo Nordisk CEO Lars Jorgenson in Denmark to discuss the high costs and limited supply of the company's popular weight loss drugs, Ozempic and Wegovy.
Novo to Supply Half of Danish Growth in 2024, Danske Says
Novo Nordisk A/S is likely to contribute about half of Denmark’s economic expansion this year, helping the nation to ...
The Sunday Business Post25m
Novo Nordisk to contribute to half of Danish GDP growth this year, Danske forecasts
Denmark: The nation’s flourishing drugmaking industry, mostly known for Novo’s obesity drugs, has been responsible for much ...
Pharmaceutical Technology13m
UAE MoHAP and Novo Nordisk partner for obesity management
The UAE has partnered with Novo Nordisk Pharma Gulf to develop a national scientific guide for obesity management and weight ...
STAT4d
New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure
Novo Nordisk’s Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a ...
BioSpace3d
Siding With Novo and Lilly, Court Agrees to First Tackle ‘Cross Cutting Issues” in GLP-1 Litigations
In agreeing with Novo Nordisk and Eli Lilly, Pennsylvania judge Karen Spencer Marston said the court should first settle ...
FiercePharma3d
Novo rekindles heart failure hopes for semaglutide with new pooled analysis
After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy ...
Novo highlights heart benefits of weight loss drug with new analysis
Novo Nordisk (NVO) posts new data to show the potential of its weight loss therapy semaglutide in reducing heart failure risk ...
Business Insider3d
Deutsche Bank Keeps Their Buy Rating on Novo Nordisk (0QIU)
In a report released on August 28, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK1,100.00. The company’s shares ...